Salute e Benessere

Embla Medical hf: Interim Report Q3 2025

Interim report Q3 2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: "Sales in Q3 2025 amounted toUSD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched...
PR Newswire
21/10/2025

Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the…

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources...
Nasdaq GlobeNewswire
21/10/2025

Neuromod Launches Online Tinnitus Masterclass

Tinnitus Masterclass Increases Tinnitus Care Accessibility Tinnitus Masterclass Increases Tinnitus Care Accessibility Tinnitus, which is commonly known as ringing in the ears, is a complex medical condition that impacts approximately 15% of the global adult population 1. Despite this prevalence, nearly half of all tinnitus patients had to wait more than two months or more for specialist tinnitus care per a 2024 Tinnitus UK report 2. Neuromod's Director of Clinical Affairs and Tinnitus...
PR Newswire
21/10/2025

BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS

On September 15, 2025, the Company issued Debentures for an aggregate principal amount of $335,670 convertible into common shares in the capital of the Company ("Shares") at any time, at the option of the holders thereof, at the closing price of the Shares on the Canadian Securities Exchange (the "CSE") on the day notice of conversion is received by the Company, subject to the pricing requirements in the policies of the CSE. The Debentures bear interest at a rate of 10% per…
PR Newswire
21/10/2025

Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical…

Liposarcoma Market Summary Liposarcoma Market Summary Discover the liposarcoma new treatment @New Treatments for Liposarcoma Key Factors Driving the Growth of the Liposarcoma Market Rising Liposarcoma Incidence and Improved Diagnosis The increasing global incidence of liposarcoma, particularly in older populations, is a major factor contributing to market growth. Advancements in diagnostic techniques, such as imaging and molecular profiling, have led to earlier and more...
PR Newswire
20/10/2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue®…

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ®, a biosimilar to Herceptin ®(trastuzumab) Tuznue ®received European Commission (EC) marketing authorization in September 2024Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct.20, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE:...
Nasdaq GlobeNewswire
20/10/2025

Alkermes to Report Third Quarter Financial Results on October 28, 2025

About Alkermes plc About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy...
PR Newswire
20/10/2025

DMS GROUP : ACCELERATION OF GROWTH IN THE 3RD QUARTER 2025

Quarterly revenue of €11.0 million, up +10% Dynamism in the Radiology business (+15% in Q3) Confirmation of the objective of accelerating growth in the 2nd half of 2025 in a less dynamic market context in France and Europe October 20, 2025 – 5:45 pm – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in…
Actusnews Wire
20/10/2025

Rigid Endoscopes Market worth $2.32 billion by 2030 with 4.9% CAGR |…

Browse in-depth TOC on "Rigid Endoscopes Market" Browse in-depth TOC on "Rigid Endoscopes Market" 450 - Tables 60 - Figures 450 - Pages By type,the rigid endoscopes market is segmented into laparoscope, urology endoscopes, gynecology endoscopes, arthroscopes, cytoscopes, neuroendoscopes, and other rigid endoscopes. Among these, the laparoscopes segment accounted for the largest market share in 2024, owing to its broad clinical utility across both diagnostic and surgical...
PR Newswire
20/10/2025

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell…

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more mature data: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFU Anzu-cel maintains a favorable tolerability profile in metastatic uveal melanoma Anti-tumor activity observed across metastases throughout the body, including liver lesions, and...
Nasdaq GlobeNewswire
20/10/2025

Compounding Pharmacy Market worth $19.41 billion by 2030 with 5.7% CAGR |…

Browse in-depth TOC on "Compounding Pharmacy Market" Browse in-depth TOC on "Compounding Pharmacy Market" 480 - Tables 60 - Figures 350 - Pages By product,the global compounding pharmacy market is divided into seven main categories based on product type: topical drugs, oral drugs, parenteral drugs, rec tal drugs, nasal drugs, ophthalmic drugs, and other products. The oral drugs segment holds the largest share in the market, driven by the demand for customized,...
PR Newswire
20/10/2025

Hyperhidrosis Treatment Market is expected to generate a revenue of USD 2.28…

For a detailed analysis of industry trends and growth drivers, explore the full Hyperhidrosis Treatment Market. For a detailed analysis of industry trends and growth drivers, explore the full Hyperhidrosis Treatment Market. Browse in-depth TOC 202 - Pages 126 – Tables 37 – Figures Global Hyperhidrosis Treatment Market Overview Market Driver 1. Rising Awareness and Diagnosis Rates of HyperhidrosisIncreasing awareness about hyperhidrosis as a genuine...
PR Newswire
20/10/2025

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection ... A New Era…

The surgery was conducted on a 68-year-old man experiencing severe headaches and loss of concentration and involved removing a 4.5-centimeter brain tumor using robotic arms. The patient was discharged fully conscious within 24 hours, a recovery time nearly four times faster than traditional brain surgeries.Hospital officials credited the robotic tumor resection with minimizing surgical trauma and accelerating recovery. According to Dr. Homoud Aldahash, Consultant of Skull Base Tumors at...
Nasdaq GlobeNewswire
20/10/2025

Bone Regeneration Market to Reach $6.0 Billion by 2027 in the short term and…

Market Introduction Market Introduction The bone regeneration market refers to the segment of the medical industry focused on restoring or replacing damaged bone tissue through biological substitutes and advanced therapeutic techniques. This market encompasses bone grafts, bone graft substitutes, and regenerative materials, which are widely used in orthopedic surgeries, dental procedures, and trauma cases. Significant developments have shaped the market, such as the increasing adoption of...
PR Newswire
20/10/2025

Patient Safety and Risk Software Market worth $2.99 billion by 2030 with 11.3%…

Browse in-depth TOC on "Patient Safety and Risk Management Solutions Market" Browse in-depth TOC on "Patient Safety and Risk Management Solutions Market" 68 - Tables 60 - Figures 350 - Pages By function,Risk & safety management solutions hold the largest share due to their central role in incident reporting, adverse event tracking, and proactive risk mitigation for hospitals and healthcare systems. These platforms are widely adopted as they address the most critical...
PR Newswire
20/10/2025

MAXIMA GRUPĖ's Audit Comittee Elected for a New Term

On October 20, 2025, UAB “Vilniaus prekyba“, the sole shareholder of MAXIMA GRUPĖ, UAB (hereinafter - MAXIMA GRUPĖ), elected the MAXIMA GRUPĖ audit committee for a new four-year term. The term of office of MAXIMA GRUPĖ’s Audit Committee, comprising Chairwoman Irena Petruškevičienė, Eglė Čiužaitė, and Matas Kasperavičius was due to expire in March 2026, at the end of their four-year term, before the completion of the audit of MAXIMA GRUPĖ‘s 2025 financial statements.In order to ensure the...
Nasdaq GlobeNewswire
20/10/2025

New NYC 'Liver ICU' Lab Transforming Liver Disease Treatments

Quin Wills, CEO and Founder of Ochre, said: "Every year, 1.5 million people die of chronic liver disease. The only true cure today is a transplant. But with only about 40,000 done globally, liver medicine has become a medical lottery — not healthcare. Quin Wills, CEO and Founder of Ochre, said:"Every year, 1.5 million people die of chronic liver disease. The only true cure today is a transplant. But with only about 40,000 done globally, liver medicine has become a medical lottery —…
PR Newswire
20/10/2025

TUMI INVITES YOU TO "GIFT JOY" THIS HOLIDAY SEASON

As TUMI concludes its milestone 50th-anniversary year, the brand celebrates its legacy through a striking palette of Black and TUMI Red—its signature Pantone, an enduring symbol of strength and purpose. Featured across some of the brand's most iconic pieces within the Alpha, Alpha Bravo, Voyageur, and 19 Degree Aluminum collections, these colors celebrate TUMI's heritage while signaling its continued evolution: bold, resilient, and built for the journey ahead. As TUMI concludes its milestone...
PR Newswire
20/10/2025

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001…

"Achieving design freeze and starting prototype production marks a major advancement for Zero Candida as we move closer to delivering a much needed solution for women suffering from VVC," said Eli Ben-Haroosh, CEO of Zero Candida Technologies. "I want to thank our engineering team for their dedication in reaching this milestone and our Clinical Advisory Board for the valuable insights we've gained throughout the process." "Achieving design freeze and starting prototype…
PR Newswire
20/10/2025

Endo Launches First and Only Generic Version of RAVICTI® (glycerol…

"This first-to-market launch of generic RAVICTI® oral liquid is a meaningful milestone for Endo and important for our Generics business as we near the planned spin-off of Par Health," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. "It expands access for patients and providers, and reinforces our commitment to quality, reliability, and leadership in complex generics." "This first-to-market launch of generic RAVICTI…
PR Newswire
20/10/2025

Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage…

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval programParis,October 20,2025.The US Food and Drug...
Nasdaq GlobeNewswire
20/10/2025

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*)…

OASIS 4 trial highlights include: OASIS 4 trial highlights include: Investigating improvements in blood sugar and cardiovascular risk factorsIn an OASIS 4 post hoc analysis, investigators explored improvements in glycemic parameters and cardiovascular risk factors for people with obesity or overweight treated with once-daily oral semaglutide 25 mg. 1 Examining the efficacy of semaglutide across formulations (pill and injectable) in women's healthAdditional post hoc analyses from...
PR Newswire
20/10/2025

Taiwan Showcases Evidence-Based TCM at CPHI Frankfurt 2025

A central focus is the series of national TCM innovations developed by the National Research Institute of Chinese Medicine (NRICM): NRICM101 and NRICM102 for COVID-19, NRICM201 for dementia, and NRICM301 for post-stroke recovery. Among these, only NRICM101 and NRICM102 have reached the market, widely recognized during the pandemic as exemplar of evidence-based TCM. A central focus is the series of national TCM innovations developed by theNational Research Institute of Chinese Medicine (NRICM)...
PR Newswire
20/10/2025

A blueprint for Digital Health Medical Technologies (DHMTs)

OutspokenPR
20/10/2025
Altri  Comunicati